February 14, 2024: NCHR supports USPSTF BRCA-Related Cancer research plan but recommends evaluating the impact of how risk information is explained in genetic counseling & treatment options. Our primary concern is providing short-term and long-term risk information and absolute risk and benefit statistics as well as relative risks and benefits.
Read More »On Health Policy
NCHR Comment- Menu Labeling: Supplemental Guidance for Industry (Edition 2)
The FDA recommends that chain restaurants publish information on calories and added sugars on standard menus and also on third-party platforms such as Grubhub and Ubereats. NCHR agrees with FDA’s plan to improve info available to consumers but urges the agency to make these recommendations mandatory to ensure the compliance needed to provide useful health information to consumers.
Read More »Medicare has different standards than the FDA. That’s how it should be
STAT News, February 2, 2024: NCHR’s Diana Zuckerman’s commentary in STAT News explains why Medicare should not pay for every medical product that FDA approves, since some are more likely to harm rather than help Medicare patients. She points out that FDA does not require diversity in clinical trials and rarely includes enough older and less healthy patients that tend to rely on Medicare.
Read More »Coalition follow-up letter to FDA regarding FDA overruling their own scientists
February 5, 2024: The Patient, Consumer, and Public Health Coalition expressed their strong concerns when the Food and Drug Administration (FDA) Center Directors publicly undermine or privately overrule the recommendations of their own scientists’ and statisticians’ regarding applications for accelerated approval and full approval.
Read More »Coalition follow-up letter to FDA regarding FDA overruling their own scientists
February 5, 2024: The Patient, Consumer, and Public Health Coalition expressed their strong concerns when the Food and Drug Administration (FDA) Center Directors publicly undermine or privately overrule the recommendations of their own scientists’ and statisticians’ regarding applications for accelerated approval and full approval.
Read More »